If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management
Key factors include: Starting Weight and BMI: Individuals with higher initial body weight may experience changes at different rates

Based on analysis of employer experiences, vendor data, and expert interviews, PHTI outlines five key recommendations for employers: Establish clear, clinically driven eligibility pathways for GLP-1 coverage Require participation in behavior, nutrition, or lifestyle change programs as a condition of coverage Provide structured support for employees who choose to taper or discontinue GLP-1 therapy Review existing vendor capabilities before adding additional point solutions Contract with vendors to drive outcomes while examining overall program costs The report identifies three critical phases where these solutions can support employers in managing their GLP-1 coverage: Initiation: Providing targeted GLP-1 coverage using clinical criteria, behavioral or AI-based screening, narrow prescribing networks, or step-therapy pathways that include lower-cost alternatives or lifestyle change programs

This clear designation protects both researchers and suppliers while ensuring appropriate use context for these research tools
Blood Sugar Management: This process helps the body maintain stable blood glucose levels
Fatigue during dose escalation can be temporary, but ongoing tiredness may point to anemia, thyroid disease, depression, sleep apnea, kidney issues, medication effects, or repeated nighttime hypoglycemia